Getting to Know the Robot: Early Studies Assess Efficacy, Costs, and Outcomes With Robotic Prostatectomy
Robot-assisted radical prostatectomy adoption into medical practice has been swift and encompassing, even as questions remain about its efficacy, added costs, and perioperative and longer-term outcomes versus alternatives.
The Role of Companion Diagnostic Testing in Payer Decision Making
Companion diagnostics can enable significant improvements in safety, efficacy, outcomes, and cost-effectiveness associated with many existing and new therapies.
Individualized Approach to Treatment for the Elderly Ovarian Cancer Patient
Stuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.
Study Supports Chemotherapy-Free Strategy in Acute Promyelocytic Leukemia
A treatment regimen rooted in traditional Chinese philosophy has emerged as a targeted approach for patients with newly diagnosed, lower-risk acute promyelocytic leukemia.
On Sunday, December 9, 2012, the Plenary Session at the 54th American Society of Hematology Annual Meeting featured several noteworthy abstracts.
Adding Vorinostat to Standard Chemotherapy Reduced the Incidence of Acute GVHD
Vorinostat added to standard chemotherapy before, during, and after hematopoietic stem-cell transplantation reduced the cumulative incidence of graft-versus-host disease.
Study Confirms Treatment Target in Patients With Polycythemia Vera
Patients with the rare form of blood cancer polycythemia vera whose hematocrit levels hover between 45% and 50% have a four-fold higher incidence of thrombotic complications.
EGFR Mutation Not a Prognostic Factor for NSCLC
Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor.
Optimizing Advanced Technologies to Improve Outcomes in Esophageal Cancer
Studies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.
Docetaxel Dosing Every 2 Weeks May Be Superior to Current Standard Regimen in CRPC
Administration of docetaxel every 2 weeks in patients with CRPC was associated with significantly longer time to treatment failure, improved OS, and produced fewer adverse events.
Novel TKI Quizartinib Sparks Remission in Some Patients With Resistant AML
Quizartinib, an investigational tyrosine kinase inhibitor, demonstrated a clinical benefit in patients with a particularly deadly form of acute myeloid leukemia.
Alterations in CYP2D6 Enzyme Affect Efficacy of Tamoxifen
Genetic or drug-induced alterations of the enzyme CYP2D6 that result in reduced metabolism of tamoxifen are associated with a higher risk of recurrence and death in women with ERâ€“positive breast cancer who receive the drug.
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.